Interstitial Lung Disease
Understanding risk factors, progression of interstitial lung abnormalities
Knowing that interstitial lung abnormalities heighten interstitial lung disease and all-cause mortality risk, it is important that pulmonologists know how to recognize and distinguish these abnormalities.
Interstitial lung disease can develop ‘in any stage’ of systemic sclerosis
SAN DIEGO — Shortness of breath, male sex, age and elevated inflammatory markers are all more predictive of new interstitial lung disease in systemic sclerosis than disease duration, according to data presented at ACR Convergence 2023.
Real-world monitoring of rheumatoid arthritis-associated ILD ‘suboptimal’
SAN DIEGO — Monitoring of rheumatoid arthritis-associated interstitial lung disease remains highly variable and “suboptimal” in the real world, according to a speaker at ACR Convergence 2023.
Researchers characterize ILD with surfactant-related gene mutations
Patients with interstitial lung disease and surfactant-related gene mutations showed progressive lung function decline and reduced survival that was comparable to that of other ILD groups, according to results published in CHEST.
Patients with asthma, COPD, ILD have reduced COVID vaccine protection
Patients with asthma, COPD and interstitial lung disease have reduced SARS-CoV-2 vaccine-specific antibody, B-cell and T-cell responses, which signals poorer protection against COVID-19, according to results published in ERJ Open Research.
FDA grants breakthrough designation to progressive pulmonary fibrosis treatment
The FDA granted breakthrough therapy designation to an oral lysophosphatidic acid receptor 1 antagonist that lowered the rate of percent-predicted FVC decline among patients with progressive pulmonary fibrosis.
Patients receiving nintedanib for SSc-ILD at increased risk for malnutrition vs placebo
Patients with systemic sclerosis-associated interstitial lung disease who receive nintedanib demonstrate a higher risk for malnutrition, compared with placebo, according to data published in Arthritis Care & Research.
Lysophosphatidic acid receptor 1 antagonist slows lung function decline in progressive PF
Receiving an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks lowered the rate of percent predicted FVC decline in progressive pulmonary fibrosis, according to a European Respiratory Society International Congress presentation.
Patients with progressing SSc-ILD should be seen ‘every 3 to 6 months’
SAN DIEGO — Rheumatologists should stratify patients with systemic sclerosis-associated interstitial lung disease into phenotypes in order to closely monitor those with progressing disease, according to a speaker here.
‘A plethora of emerging treatments’ coming for idiopathic inflammatory myopathies
SAN DIEGO — Clinical trials exploring intravenous immunoglobulin and Janus kinase inhibition headline a robust pipeline for idiopathic inflammatory myopathies, according to a speaker at the 2023 Congress of Clinical Rheumatology West.